Company Overview

Nutra Pharma Corporation is a United States-based biopharmaceutical company that operates in the biotechnology sector. Founded in 2000, the company is primarily focused on the acquisition, licensing, and commercialization of pharmaceutical products and technologies aimed at managing a range of severe conditions, including pain, neurological disorders, cancer, and autoimmune and infectious diseases. The company's business model encompasses the research, development, and eventual marketing of both over-the-counter (OTC) and prescription-based healthcare solutions.

A cornerstone of Nutra Pharma???s proprietary technology involves the use of synthesized compounds derived from cobra venom. This unique approach forms the basis for their key pipeline drug candidates as well as their commercialized homeopathic OTC product line, targeting an array of pain and inflammatory conditions in humans and animals.

Core Operations and Therapeutic Focus

The company???s operations are segmented into two main areas: the commercialization of its marketed over-the-counter products and the research and development of its pipeline pharmaceutical drugs.

1. Over-the-Counter (OTC) Products and Commercialization

Nutra Pharma maintains a portfolio of non-narcotic and non-addictive OTC pain management products that are clinically proven to treat moderate to severe pain. The company's strategy includes bringing manufacturing capabilities in-house to increase production capacity for this product line. These commercialized offerings include:

• Nyloxin: This is an over-the-counter pain reliever offered as an oral spray, designed to treat various types of pain such as lower back pain, migraines, and neck aches.
• Nyloxin Extra Strength: A non-narcotic and non-addictive topical and oral treatment formulated for the relief of more severe pain in humans.
• Pet Pain-Away: An over-the-counter pain reliever specifically marketed for use in domestic animals, namely dogs and cats.
• Equine Pain-Away: An OTC topical solution developed to relieve pain in horses.
• Luxury Feet: A specialized over-the-counter pain reliever intended for the topical treatment of foot pain, particularly that resulting from wearing high heels.

2. Pharmaceutical Research and Development Pipeline

Nutra Pharma's long-term value is centered on its pipeline of drug candidates that are in various stages of development, all of which utilize the company's core technology based on synthesized cobra venom derivatives. The developmental programs focus on critical, unmet medical needs within the neurological, autoimmune, and infectious disease categories. Key drug candidates in the pipeline include:

• RPI-78M (Neuroscience and Autoimmune): This candidate is in development to treat a significant spectrum of neurological and autoimmune diseases. The targeted conditions include debilitating illnesses such as Multiple Sclerosis (MS), Myasthenia Gravis, Rheumatoid Arthritis, Adrenomyeloneuropathy, and Amyotrophic Lateral Sclerosis (ALS).
• RPI-MN (Antiviral): This drug is being developed as a potential treatment for viral diseases, with a primary focus on Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) and Herpes. It is also being investigated for general anti-viral applications.
• RPI-78: This molecule is a pain and arthritis candidate being advanced for pharmaceutical applications.
• RPI-70: A development-stage drug being explored for its potential in pain management.

The company's strategic focus is on the commercialization of its existing OTC products to generate revenue while concurrently advancing its prescription drug candidates through the regulatory and clinical trial process for neurological, autoimmune, and infectious diseases. Nutra Pharma Corporation is committed to providing options for patients and customers through innovative pharmaceutical and life science solutions.